Ovarian Neoplasms: all 2,759 studies

Page 14 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.

• A Biomarker Screening Protocol for Participants With Solid TumorsTerminatedNCT05891197
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingNCT05891171Phase 1
• Abdominopelvic Cancer PrehabilitationCompletedNCT05887531Not applicable
• Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion ChemotherapyStatus unknownNCT05877911Phase 2
• REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1TerminatedNCT05870748Phase 2/3
• Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLDCompletedNCT05868889
• Early Assessment of Ovarian Cancer Aggressiveness by Metabolic ImagingSuspendedNCT05866679Phase 1
• A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsCompletedNCT05864144Phase 1/2
• A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin AmericaActive, not recruitingNCT05857397
• VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIESStatus unknownNCT05840029
• Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial CancerTerminatedNCT05833321Not applicable
• The Efficacy and Safety of The Fuzuloparib Combination With BevacizumabStatus unknownNCT05819060Phase 2
• Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian CancerCompletedNCT05815862Phase 2
• Individualized Precision Treatment Based on Ovarian Cancer Organoid ModelStatus unknownNCT05813509Not applicable
• Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid TumorsActive, not recruitingNCT05799274Phase 1
• Experience in Borderline Ovarian TumorsStatus unknownNCT05791838
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsActive, not recruitingNCT05787587Phase 1
• e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot StudyActive, not recruitingNCT05786456Not applicable
• NKG2D CAR-NK & Ovarian CancerStatus unknownNCT05776355Not applicable
• A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian CancerCompletedNCT05775549
• Study of RO7515629 in Participants With HLA-G Positive Solid TumorsTerminatedNCT05769959Phase 1
• Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic EvaluationStatus unknownNCT05763472
• Endocrine Disruptors and Life STILe in Breast Cancer DevelopmentStatus unknownNCT05748353
• Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)Active, not recruitingNCT05743517Not applicable
• Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the RuleCompletedNCT05741554
• Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian CancerWithdrawnNCT05736952Phase 2
• Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world StudyCompletedNCT05734911
• Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer PredispositionCompletedNCT05721326Not applicable
• PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian CarcinomaWithdrawnNCT05714306Phase 1/2
• A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)CompletedNCT05708950Phase 1/2
• Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Prospective Study)Status unknownNCT05693987
• Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study)Status unknownNCT05693974
• Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) InterventionActive, not recruitingNCT05677048Not applicable
• Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian CancerWithdrawnNCT05672095Phase 1/2
• Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance TherapyStatus unknownNCT05669768Phase 2
• Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous CarcinomaStatus unknownNCT05665023Phase 2
• A Performance Study of (Opportunistic) SalpingectomyCompletedNCT05646680Not applicable
• MicroFluO: FLUorescence-guided Surgery for Ovarian CancerCompletedNCT05633836Not applicable
• A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian CancerStatus unknownNCT05622890Phase 3
• A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With CisplatinStatus unknownNCT05620654Phase 1
• AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian CancerActive, not recruitingNCT05617755Phase 1
• Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian CancerActive, not recruitingNCT05605535Phase 2
• ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)TerminatedNCT05601752Phase 2
• Genetic Testing in African AmericansActive, not recruitingNCT05591131Not applicable
• Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian CarcinomaStatus unknownNCT05576519
• Role of Laparoscopy in Assessing Resectability of Ovarian CancerCompletedNCT05564234Not applicable
• Gynaecology Exercise and Mindfulness StudyStatus unknownNCT05561413Not applicable
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian NeoplasmsCompletedNCT05553067
• A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced CancersActive, not recruitingNCT05544929Phase 1
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryTerminatedNCT05538624Phase 1/2
• Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian CancerStatus unknownNCT05523804
• Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)CompletedNCT05523700Not applicable
• Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian OriginActive, not recruitingNCT05514028
• Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to PlatinumCompletedNCT05512676
• Development, Implementation and Evaluation of an Individual Decision Aid in Swedish Cancer Screening ProgramsWithdrawnNCT05512260Not applicable
• Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay.CompletedNCT05504174
• Oral AMXT 1501 Dicaprate in Combination With IV DFMOTerminatedNCT05500508Phase 1/2
• Ovarian Cancer Individualized Scoring System Scoring SystemStatus unknownNCT05496517
• Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
• Role of the ATP7A Transporter in Ovarian CancerCompletedNCT05490407Not applicable
• A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor ExposureActive, not recruitingNCT05489926Phase 2
• A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer PatientsWithdrawnNCT05479045Phase 2
• A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP InhibitorActive, not recruitingNCT05475184Phase 2
• Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)CompletedNCT05472532Not applicable
• Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian CancerActive, not recruitingNCT05467670Phase 2
• PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube CancerActive, not recruitingNCT05465941Phase 2
• A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced CancerWithdrawnNCT05465590Early Phase 1
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 1
• Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)CompletedNCT05461430
• Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation.Status unknownNCT05458973
• Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancerActive, not recruitingNCT05456685Phase 2
• ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerActive, not recruitingNCT05446298Phase 2
• Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerActive, not recruitingNCT05445778Phase 3
• First-line Olaparib Combined With Bevacizumab Maintenance TherapyStatus unknownNCT05440578
• Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian CancerStatus unknownNCT05422183Phase 2
• Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal CancerActive, not recruitingNCT05415709Early Phase 1
• Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised ManagementCompletedNCT05415527Not applicable
• Intraperitoneal Chemotherapy Versus Triweekly ChemotherapyCompletedNCT05410938
• A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPiStatus unknownNCT05385068Phase 2
• Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian CancerStatus unknownNCT05375526Not applicable
• Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian CancerCompletedNCT05372692Not applicable
• Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian CancerStatus unknownNCT05371301Phase 3
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnNCT05368506Early Phase 1
• Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type PatientCompletedNCT05368207Not applicable
• A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic CancersCompletedNCT05360680Phase 1
• Combination of Olaparib and Navitoclax in Women with HGSC and TNBCActive, not recruitingNCT05358639Phase 1
• The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian CancerTerminatedNCT05352217
• A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Active, not recruitingNCT05335993Phase 2
• Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)TerminatedNCT05329545Phase 3
• A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian CancerStatus unknownNCT05325229Phase 2
• CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)Active, not recruitingNCT05316181Phase 3
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• Chromosomal Instability in Ovarian CancerStatus unknownNCT05310357
• Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian CancerStatus unknownNCT05310344Phase 2
• Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian CancerCompletedNCT05300828
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRsCompletedNCT05292859
• The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug ScreeningStatus unknownNCT05290961

← Ovarian Neoplasms overview